Biohaven Ltd. (BHVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biohaven Ltd. (BHVN) has a cash flow conversion efficiency ratio of -1.158x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-149.92 Million) by net assets ($129.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biohaven Ltd. (BHVN) total market value for the company's overall valuation and market capitalisation.
Biohaven Ltd. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Biohaven Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Biohaven Ltd. for real-time trading data and today's change.
Biohaven Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohaven Ltd. ranked by their cash flow conversion efficiency. Review BHVN financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hoist Finance AB
ST:HOFI
|
0.067x |
|
Brightstar Lottery PLC
NYSE:BRSL
|
0.078x |
|
ZAI LAB LTD0000006
F:1ZLB
|
-0.018x |
|
PSMC CO. Ltd
KQ:024850
|
-0.032x |
|
Genting Bhd
KLSE:3182
|
0.082x |
|
Willfar Information Technology Co Ltd
SHG:688100
|
0.033x |
|
Expro Group Holdings NV
NYSE:XPRO
|
0.054x |
|
Ams AG
SW:AMS
|
-0.107x |
Annual Cash Flow Conversion Efficiency for Biohaven Ltd. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Biohaven Ltd. from 2017 to 2025. Also see BHVN total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.07 Million | $-609.44 Million | -11.704x | -750.85% |
| 2024-12-31 | $423.44 Million | $-582.45 Million | -1.376x | -77.47% |
| 2023-12-31 | $427.98 Million | $-331.73 Million | -0.775x | -40.28% |
| 2022-12-31 | $538.77 Million | $-297.69 Million | -0.553x | +64.13% |
| 2021-12-31 | $94.69 Million | $-145.84 Million | -1.540x | -55.69% |
| 2020-12-31 | $76.78 Million | $-75.96 Million | -0.989x | -101.95% |
| 2019-12-31 | $-7.42 Million | $-377.33 Million | 50.826x | +3990.94% |
| 2018-12-31 | $150.92 Million | $-197.14 Million | -1.306x | -81.82% |
| 2017-12-31 | $131.97 Million | $-94.81 Million | -0.718x | -- |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more